Kargbo Robert B
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS Med Chem Lett. 2024 Aug 22;15(9):1427-1429. doi: 10.1021/acsmedchemlett.4c00405. eCollection 2024 Sep 12.
Recent advancements in pharmaceutical and gene therapy research have led to the development of novel compounds and delivery systems that target critical areas of unmet medical needs, including drug-resistant bacterial infections, cancer, and genetic diseases. This Patent Highlight reviews the key findings from three recent patents that describe innovations in tricyclic quinolone compounds and adeno-associated virus (AAV) vectors for gene editing. These innovations demonstrate significant progress in the treatment of antibiotic-resistant bacterial infections, BCL6-dependent cancers, and the efficient delivery of CRISPR-based gene editing tools.
制药和基因治疗研究的最新进展已促成新型化合物和递送系统的开发,这些化合物和递送系统针对未满足的医疗需求的关键领域,包括耐药细菌感染、癌症和遗传疾病。本专利亮点回顾了最近三项专利的主要发现,这些专利描述了用于基因编辑的三环喹诺酮化合物和腺相关病毒(AAV)载体的创新。这些创新在耐抗生素细菌感染、BCL6依赖性癌症的治疗以及基于CRISPR的基因编辑工具的有效递送方面取得了重大进展。